Mitchel Sklar, MD
Interventional Cardiology · Providence, RINPI 1952306185
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by Abbott at 55.5% of the total. 2025 is the largest year on record at $1,383, more than ten times the $119 reported in 2023. That places this record below the midpoint for interventional cardiology clinicians in RI, where the typical reported total is $3,343.
Across 22 payments — averaging $106.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Medtronic$783
- Abiomed$168
- Teleflex LLC$57
- Boston Scientific$36
Across 3 payments — averaging $1666.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$5K
What the payments were for
- Travel & lodging$1,23052%
- Food & beverage$1,11848%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $1,303 |
| Medtronic | 10 | $783 |
| Abiomed | 2 | $168 |
| Teleflex LLC | 1 | $57 |
| Boston Scientific | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIENCE SKYPOINT$1,098
- SYMPLICITY G3$573
How this compares
$2,348 in reported general payments places this provider in the 40th percentile of 23 interventional cardiology providers in Rhode Island.
See all interventional cardiology providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $326,249 |
| XareltoRivaroxaban | 150 | $151,507 |
| EntrestoSacubitril/Valsartan | 64 | $90,809 |
| JardianceEmpagliflozin | 46 | $55,988 |
| Repatha SureclickEvolocumab | 33 | $36,862 |
| BrilintaTicagrelor | 30 | $20,422 |
| Praluent PenAlirocumab | 24 | $18,168 |
| Dofetilide | 21 | $7,449 |
| Atorvastatin Calcium | 515 | $6,482 |
| Metoprolol Succinate | 388 | $5,853 |
| Ezetimibe | 188 | $5,846 |
| Fenofibrate | 31 | $4,917 |
| Losartan Potassium | 263 | $2,961 |
| Rosuvastatin Calcium | 173 | $2,895 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 65 | $2,304 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Providence
- Peter SoukasProvidence$798K
- Jinnette AbbottProvidence$156K
- Marwan SaadProvidence$57K
- Hafiz ImranProvidence$18K
- Paul GordonProvidence$13K
- Omar HyderProvidence$9K
- Anum AsifProvidence$6K
- Ahmed ElkaryoniProvidence$3K
- Barry SharafProvidence$3K
- Saraschandra VallabhajosyulaProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.